Abbott Laboratories (ABT) EPS (Weighted Average and Diluted) (2009 - 2026)

Abbott Laboratories has disclosed EPS (Weighted Average and Diluted) across 18 years of filings, most recently posting $0.61 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at $0.61, down 19.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.58 (down 53.51% YoY), and the FY2025 annual result was $3.72, down 51.31% from the prior year.
• EPS (Weighted Average and Diluted) came in at $0.61 for Q1 2026 at Abbott Laboratories, down from $1.02 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $5.26 in Q4 2024 to a low of $0.59 in Q4 2022.
• The 5-year median for EPS (Weighted Average and Diluted) is $0.82 (2023), against an average of $1.13.
• Across the five-year window, EPS (Weighted Average and Diluted) soared 478.02% in 2024 and sank 80.61% in 2025, its largest moves.
• Abbott Laboratories' EPS (Weighted Average and Diluted) stood at $0.59 in 2022, then soared by 54.24% to $0.91 in 2023, then surged by 478.02% to $5.26 in 2024, then plunged by 80.61% to $1.02 in 2025, then tumbled by 40.2% to $0.61 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $0.61 (Q1 2026), $1.02 (Q4 2025), and $0.94 (Q3 2025), per Business Quant data.